

## AMENDMENT

### In the Claims

(Please amend claims 4 and 6 as indicated below.)

- C<sup>1</sup>
4. (Twice Amended) The antibody according to claim 1, which is generated using a polypeptide encoded by a base sequence set out in SEQ ID NO: 1 as an antigen.

- C<sup>2</sup>
6. (Twice Amended) The antibody according to claim 1 wherein the antibody is generated using a fusion protein comprising a LAR phosphatase domain and another protein as an immunogen.

## REMARKS

### I. Prosecution History

The application as filed contained thirty-nine claims. In a preliminary amendment dated December 8, 2000, the Applicants amended claims 4-7, 10, 12-13, 15, 16, 19, 20, 22, 24, 26, 28, 29, 32, 33, 35, 36, 38, and 39; and amended the Sequence Listing to comply with US PTO format requirements (37 C.F.R. § 1.821) without substantially changing any sequences in any way. In a second preliminary amendment dated January 10, 2001, the Applicants amended claim 39. In the outstanding Office action, claims 20-26 and 29-39 were withdrawn from consideration as being drawn to a non-elected invention. Although the restriction requirement has been made final, the Applicants reserve the right to petition therefrom.

### II. Explanation of Amendments

A marked up version of the changes made to the claims can be found in Appendix A hereto. Support for the amended claims is found throughout the specification including at page 8, lines 17-20, which describes an antibody directed against an antigen and at page 9, lines 15-17, which describes an antibody directed against a fusion protein comprising an immunogen, and GST. As a convenience to the examiner, the Applicants have set forth all claims still pending in Appendix B as they should appear after entry of the foregoing amendment.